StemCells Inc. (Nasdaq: STEM) is a clinical-stage biotechnology company focused on the development and commercialization of cell-based therapeutics to treat diseases of the central nervous system and liver. Though controversial to many people, cell-based discoveries are important in medical and scientific advances.

Dyax Corporation, a Massachusetts biopharmaceutical company, has announced third quarter revenues of $5.5 million, compared with $2.6 million for the comparable quarter in 2007, an increase of 111%. In addition, revenues for the nine-month period ending September 30, 2008, increased to $12.0 million, compared to $7.9 million for the comparable nine-month period in 2007, an increase of nearly 52%.

Dyax Corp. (Nasdaq: DYAX) focuses on the advancement of novel biotherapeutics, such as those for the treatment of hereditary angiodema (HAE), a rare and potentially life-threatening condition that occurs in about one in every 10,000 to 50,000 people.

Dyax Corp. (Nasdaq: DYAX) is a clinical-stage drug company focused on the discovery, development and commercialization of biotherapeutics for oncology and inflammatory conditions.